# CB MedTech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cb-medtech

- Industry: Healthcare
- Headquarters: Suzhou, China
- Website: www.cb-medtech.com/
- Latest round: Series B (Apr 29, 2026)
- Investors on record: 2

## About

CB MedTech, based in Suzhou, China, focuses on developing advanced medical technology solutions to improve patient care and enhance operational efficiency in healthcare environments.Founded in 2017, CB MedTech specializes in medical technology solutions. The company has engaged in one significant deal as of April 2026, indicating its operational focus on growth and development in the medical sector. The founder's background and previous ventures are not detailed in the available information.CB MedTech specializes in the development and provision of advanced medical technology solutions aimed at enhancing patient care and operational efficiency in healthcare settings. Their core offerings include innovative medical devices, diagnostic tools, and software solutions designed to address specific healthcare challenges, such as improving patient monitoring and streamlining clinical workflows. These products are intended for use in hospitals, outpatient clinics, and various healthcare facilities, catering to a diverse range of end users including healthcare professionals, administrators, and patients. CB MedTech's solutions have been released over several years, targeting markets across North America, Europe, and parts of Asia, significantly contributing to improved healthcare delivery in these regions.CB MedTech generates revenue through a structured model that includes direct sales to healthcare providers, partnerships with distributors, and potentially subscription-based services for software solutions. Typical transactions involve the sale of medical devices and software, which include flagship products that offer critical functionalities for health monitoring and data management. Clients, primarily healthcare institutions and professionals, engage in purchasing agreements that specify terms for volume sales and pricing tiers based on product categories. These pricing plans are designed to accommodate various budgetary constraints of healthcare providers while ensuring access to state-of-the-art medical technology, thereby facilitating ongoing revenue streams for the company.In April 2026, CB MedTech raised an undisclosed amount of Series B funding from new investors Tsing Song Capital and Longtai Investment. The company will utilize this Series B funding to accelerate its product development process, optimize its clinical testing services, and further expand its market share in the transplant medicine field. Future developments may include the launch of new products aimed at enhancing patient care and operational efficiency, with strategic plans to penetrate additional markets in Asia and Europe by the end of 2026.

## Funding rounds

- Series B, Apr 29, 2026 — Tsing Song Capital, Longtai Investment

## Investors

- Tsing Song Capital (https://capitalatlas.ai/funds/tsing-song-capital) — Series B
- Longtai Investment (https://capitalatlas.ai/funds/longtai-investment) — Series B